SK-N-SH細(xì)胞

運(yùn)輸方式： 凍存運(yùn)輸

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來源： 人

器官來源： 大腦

年限： 4 years

生長狀態(tài)： 貼壁生長

ATCC Number： HTB-11?

相關(guān)**： 神經(jīng)母細(xì)胞瘤

數(shù)量： 大量

Designations: SK-N-SH

Depositors: G Trempe, LJ Old

SK-N-SH細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: brain

Disease: neuroblastoma

Derived from metastatic site: bone marrow

Cellular Products: plasminogen activator

shows increased expression of M-CSF after treatment with amyloid-beta peptide

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: SK-N-SH細(xì)胞The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

Applications: transfection host

Antigen Expression: Blood Type A; Rh+

DNA Profile (STR): Amelogenin: X

CSF1PO: 11

D13S317: 11

D16S539: 8,13

D5S818: 12

D7S820: 7,10

THO1: 7,10

TPOX: 8,11

vWA: 14,18

Cytogenetic Analysis: The cell line is hyperdiploid human female (XX), with the modal chromosome number of 47. Normal chromosomes N9 and N22 are single. SK-N-SH細(xì)胞One copy of each of these chromosomes is structurally altered to form the two marker chromosomes 9q+ and 22q+., Chromosomes N7 is trisomic. Extra bands were found on one copy of chromosome N7, thereby forming a marker chromosome as described by R.C. Seeger. May have been translocated in part(s) to the q arms of chromosomes N9 and N22.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1

Me-2, 2

PGM1, 1

PGM3, 1

Age: 4 years

Gender: female

Comments: The SK-N-SH line was developed by J.L. Biedler and differs from SK-N-MC (see ATCC HTB-10) in that it exhibits a longer doubling time and higher levels of dopamine - beta - hydroxylase.

SK-N-SH has been used as a target cell line in cell mediated cytotoxicity assays.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended

Medium Renewal: 1 to 2 times per week

Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. SK-N-SH細(xì)胞Allow the flask to sit at room temperature (or at 37C) until the cells detach.

Add fresh culture medium, aspirate and dispense into new culture flasks.

Preservation: Culture medium, 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003

recommended serum:ATCC 30-2020

References: 1191: Gilbert LC, Wachsman JT. Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase. Biochim. Biophys. Acta 704: 450-460, 1982. PubMed: 7052133

2154: Spengler BA, et al. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells established in vitro. In Vitro 8: 410, 1973.

22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

23260: Bluestein HG. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 75: 3965-3969, 1978. PubMed: 279013

26318: Seeger RC, et al. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 37: 1364-1371, 1977. PubMed: 856461

29165: Yan SD, et al. Amyloid-beta peptide-Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94: 5296-5301, 1997. PubMed: 9144231

32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024

32524: Chang YE, et al. Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. J. Virol. 70: 3938-3946, 1996. PubMed: 8648731

32725: He B, et al. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma134.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Virol. 70: 84-90, 1996. PubMed: 8523596

32757: Yoshikawa T, et al. Downstream regulatory elements increase acute and latent herpes simplex virus type 2 latency-associated transcript expression but do not influence recurrence phenotype or establishment of latency. J. Virol. 70: 1535-1541, 1996. PubMed: 8627672